Lilly (LLY), Boehringer Ingelheim Report Linagliptin plus ACE/ARB Post-Hoc on UACR Hits Primary Endpoint

Go back to Lilly (LLY), Boehringer Ingelheim Report Linagliptin plus ACE/ARB Post-Hoc on UACR Hits Primary Endpoint